Linfomas
GLUN
Hospital Universitario de Donostia
San Sebastián, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Donostia (8)
2024
-
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 17, pp. 3704-3714
-
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
Blood Cancer Journal, Vol. 14, Núm. 1
2023
-
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
Journal for immunotherapy of cancer, Vol. 11, Núm. 2
2021
-
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
Blood Cancer Journal, Vol. 11, Núm. 12
2020
-
Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document
Bone Marrow Transplantation, Vol. 55, Núm. 4, pp. 811-817
2016
-
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899
-
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients
Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84
2013
-
Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952